Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.25    -0.06 (-1.39%)
Bid:
4.20
Ask:
4.25
Spread: 0.05 (1.19%)
Market Cap: £203.98m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Business Outlook Update

21 May 2018 07:00

RNS Number : 6478O
Seeing Machines Limited
21 May 2018
 

Seeing Machines Limited

Business Outlook Update

 

21 May 2018

Seeing Machines Limited (AIM: SEE) ("Seeing Machines" or the "Company"), an industry leader in computer vision technologies which enable machines to see, understand and assist people, provides an updated business outlook for the current fiscal year.

The Company has been informed by its manufacturer partner that, owing to a global shortage in traditionally short lead-time parts (capacitors and power supply) which are used in the Company's second-generation fleet product, Guardian Gen 2, production of a number of units that were due to be shipped shortly, will now be delayed by approximately six weeks. Whilst sales of these units have been agreed, the shipping of these units is now expected to be delayed accordingly, resulting in this revenue now expected to fall outside of the current financial year. Based on performance to date, existing sales pipeline and revised manufacturing schedule, the Board of Seeing Machines now revises its FY18 forecast and projects to achieve sales in the range of A$30M to A$35M, versus a previous outlook of A$38M to A$43M, as provided in October 2017. Whilst the Board of Seeing Machines is disappointed by this delay, the revised outlook still represents a doubling of FY17 sales for the FY18 period.

Seeing Machines remains optimistic and excited by the large and fast growing market opportunities across all transport sectors. The Fleet business has very strong momentum, with an installed base of 10,000 units, around the world and a strong pipeline of sales opportunities, representing total commercial value of over A$200M through engagements with large transport and logistics companies in Asia Pacific, Europe, UK, the Middle East and USA, and a growing ecosystem of distributors globally.

The Automotive opportunity continues to grow with increasing interest from automotive OEMs and suppliers to deliver driver monitoring into more platforms and models of cars around the world as represented by recently announced design awards with two premium German OEMs.

Seeing Machines' Aviation business is developing steadily as the Company continues to work with significant industry brands to shape tailored solutions to enhance safety with eye-tracking systems for evidence based pilot training, support systems in managing pilot fatigue and air traffic controller alertness systems.

The Off-Road and Rail businesses are progressing well and are performing in line with management's expectations.

More recently, the announcement by the European Commission of "Europe on the Move: Agenda for safe, clean and connected mobility" will see driver monitoring technology mandated for EU vehicles from 2021, and affirms the relevance of Seeing Machines' technology. This will undoubtedly create increased demand across the Company's focused transport sectors globally.

The Commission announced that new models of vehicles are to be equipped with advanced safety features, and specifically identifies drowsiness and attention detection for cars, vans, trucks and buses; distraction recognition and prevention for cars, vans, trucks and buses, with Seeing Machines currently one of only a few companies in the world who are well positioned to provide this technology to leading global OEMs.

 

Enquiries:

Seeing Machines Limited

www.seeingmachines.com / +61 2 6103 4700

Ken Kroeger, Executive Chairman & Interim CEO

Media inquiries

 

Ken.Kroeger@seeingmachines.com

Sophie.Nicoll@seeingmachines.com

Cenkos Securities plc (Nominated Adviser and Joint Broker)

+44 131 220 6939

Neil McDonald

Beth McKiernan

Pete Lynch

Canaccord Genuity Limited (Joint Broker)

+44 20 7523 8000

Simon Bridges

Richard Andrews

Alexander Napier

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

About Seeing Machines

Seeing Machines (LSE: SEE) is an industry leader in computer vision technologies which enable machines to see, understand and assist people. The Company deploys its FOVIO machine learning vision platform to deliver real-time understanding of drivers through AI analysis of heads, faces and eyes for Driver Monitoring Systems (DMS), which monitor driver attention state including drowsiness and distraction. DMS is increasingly considered a core automotive safety technology as well as an enabling technology for ADAS/Autonomous Driving. The Company's pioneering commercial fleet solution (Guardian) delivers an after-market, in-cabin safety intervention system with 24/7 monitoring and cloud analytics services delivered on a telematics SaaS basis. The Company also serves Aviation, Rail and Off-Road markets, and they are seeking to innovate in new markets. A global company based in Canberra Australia, with offices and people in Asia, Europe and USA, Seeing Machines delivers multi-platform solutions from embedded software and processors to aftermarket system and service solutions to industry leaders globally. www.seeingmachines.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFKKDBDBKDKPB
Date   Source Headline
21st May 20097:58 amRNSDirector Shareholding
11th Mar 20097:00 amRNSReviewed Interim Results
18th Feb 20097:00 amRNSRestructuring of the business
28th Jan 20099:41 amRNSTrading update and notice of results
1st Dec 20088:14 amRNSChange of Registered Office
27th Nov 20088:08 amRNSResult of AGM
29th Oct 200810:52 amRNSNotice of AGM
23rd Sep 20087:00 amRNSFinal Results
17th Sep 20088:37 amRNSNotice of Final Results
26th Aug 20088:33 amRNSNEW FACEAPI PRODUCT RELEASE
23rd Jul 20087:37 amRNSFirst Expected Profit Report
7th May 20088:08 amRNSNORTH AMERICAN OPERATION
7th Apr 200812:00 pmRNSChange of Broker
4th Mar 20087:59 amRNSInterim Results
4th Mar 20087:51 amRNSMajor contract gain
13th Feb 20088:27 amRNSHolding in Company
28th Dec 20079:11 amRNSAnnual Report
11th Dec 200710:54 amRNSChange of Adviser
29th Nov 200710:03 amRNSAGM Results
8th Nov 200712:38 pmRNSDirector/PDMR Shareholding
8th Nov 200712:34 pmRNSGlaucoma Device at AAO
31st Oct 20079:26 amRNSCompletion of Placing-Replace
31st Oct 20077:01 amRNSCompletion of Placing
26th Oct 20079:35 amRNSShareholder Approval
17th Oct 20072:21 pmRNSDirector/PDMR Shareholding
15th Oct 20079:23 amRNSCFO Appointment
25th Sep 200710:23 amRNSFurther Placing
24th Sep 20071:12 pmRNSFinal Results
24th Sep 20071:00 pmRNSFundraising
15th Aug 200712:43 pmRNSAIM Rule 26 Compliance
15th Aug 20079:27 amRNSFDA Approval for Truefield
2nd Jul 20077:01 amRNSNew Product Releases
29th Jun 200710:11 amRNSMaster License Agreement
22nd May 200711:15 amRNSLicensing agreement signed
8th May 20077:02 amRNSGlaucoma Device Demonstrated
28th Mar 20072:40 pmRNSInterim Results
14th Mar 200710:45 amRNSAward win for glaucoma device
12th Mar 20077:02 amRNSAddition to product released
19th Dec 200610:06 amRNSTotal Voting Rights
30th Nov 20068:27 amRNSAGM Statement
9th Nov 20067:01 amRNSGlaucoma Study Re-commences
2nd Nov 20067:01 amRNSNew Product
19th Oct 20065:38 pmRNSFinal Results - Replacement
19th Oct 200611:29 amRNSFinal Results
18th Oct 200611:04 amRNSDirectorate Change
17th Oct 20063:20 pmRNSNew Version of faceLAB
21st Sep 20064:41 pmRNSIssue of Equity
18th Sep 200611:24 amRNSAutomotive progress
18th Sep 20069:45 amRNSGlaucoma Grant Signed
30th Aug 200611:46 amRNSClinical Study Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.